Investigation of P2X7 Functionality in Cancer
Research type
Research Study
Full title
Investigation of P2X7 Functionality in Cancer
IRAS ID
158229
Contact name
Beatriz Goyenechea
Contact email
Research summary
Biosceptre has identified a novel cancer target, non functional (nf)-P2X7. The nf-P2X7 receptor is present in the majority of cancer types but is not found in healthy tissue. Existing data show that antibodies binding to nf-P2X7 have the potential to treat many types of cancer avoiding the toxicity seen with the majority of existing cancer drugs, nf-P2X7 also has the potential to provide a novel approach for developing new cancer diagnostics. Biosceptre is developing both therapeutic and diagnostic products containing antibodies that bind to nf-P2X7. Antibodies have been generated against nf-P2X7 and the purpose of this study is to characterise those antibodies, to prove their binding efficacy to the nf-P2X7 target in cancerous cells from banked samples taken from patients suffering chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL), and to identify techniques in which these antibodies could be used in the future for both therapeutic and diagnostic applications.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
14/LO/1892
Date of REC Opinion
16 Oct 2014
REC opinion
Favourable Opinion